menu
    • menu
    [{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Milademetan","moa":"MDM2-p53 complex","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Guggenheim Securities"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Milademetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Milademetan","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Milademetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Milademetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Milademetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Pathos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Milademetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Rain Oncology \/ Pathos","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Pathos"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Pathos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Milademetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Rain Oncology \/ Pathos","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Pathos"}]

    Find Clinical Drug Pipeline Developments & Deals for Milademetan

    Menu

    Milademetan

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rain Oncology

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Rain Oncology

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Milademetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Pathos

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Pathos AI Completes Acquisition of Rain Oncology

                            Details : Through the acquisition of Rain Oncology, Pathos gains access to its product canditate RAIN-32 (milademetan), a small molecule, oral inhibitor of the p53-MDM2 complex that reactivates p53.

                            Brand Name : RAIN-32

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 26, 2024

                            Lead Product(s) : Milademetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Pathos

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rain Oncology

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Rain Oncology

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Milademetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Pathos

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Va...

                            Details : Through the acquisition of Rain Oncology, Pathos gains access to its product canditate RAIN-32 (milademetan), a small molecule, oral inhibitor of the p53-MDM2 complex that reactivates p53.

                            Brand Name : RAIN-32

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 13, 2023

                            Lead Product(s) : Milademetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Pathos

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Rain Oncology

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Rain Oncology

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Milademetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical Programs

                            Details : RAIN-32 (milademetan) is an oral small molecule inhibitor of the p53-MDM2 complex that reactivates p53. It has demonstrated antitumor activity in an MDM2- amplified subtype of liposarcoma (LPS) and other solid tumors.

                            Brand Name : RAIN-32

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 30, 2023

                            Lead Product(s) : Milademetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Rain Oncology

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Rain Oncology

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Milademetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rain Oncology Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for the Treatment of Dediffer...

                            Details : RAIN-32 (milademetan) is an oral small molecule inhibitor of the p53-MDM2 complex that reactivates p53. Milademetan has demonstrated antitumor activity in an MDM2- amplified subtype of liposarcoma (LPS) and other solid tumors.

                            Brand Name : RAIN-32

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 22, 2023

                            Lead Product(s) : Milademetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Rain Oncology

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Rain Oncology

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Milademetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Phase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology

                            Details : RAIN-32 (milademetan) is an oral small molecule inhibitor of the p53-MDM2 complex that reactivates p53. Milademetan has demonstrated antitumor activity in an MDM2- amplified subtype of liposarcoma (LPS) and other solid tumors.

                            Brand Name : RAIN-32

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 23, 2023

                            Lead Product(s) : Milademetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Rain Oncology

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Rain Oncology

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Milademetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer Symposium

                            Details : Rain’s lead product, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by...

                            Brand Name : RAIN-32

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 23, 2022

                            Lead Product(s) : Milademetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Rain Oncology

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Rain Oncology

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Milademetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rain Therapeutics Announces an Oral Presentation at the Connective Tissue Oncology Society Annual Meeting

                            Details : Rain’s lead product candidate, RAIN-32 (milademetan), an oral small molecule, inhibitor of mouse double minute 2 (MDM2) is being developed in patients with wildtype tumor protein 53 (p53) cancers that are also exhibiting MDM2 dependence.

                            Brand Name : RAIN-32

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 17, 2022

                            Lead Product(s) : Milademetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Rain Oncology

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Rain Oncology

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Milademetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Guggenheim Securities

                            Deal Size : $50.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Rain Therapeutics Announces $50 Million Registered Offering of Common Stock

                            Details : Rain intends to use the net proceeds from this offering for clinical development of pipeline candidates including RAIN-32 (milademetan), commercial launch preparation, working capital and general corporate purposes.

                            Brand Name : RAIN-32

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 04, 2022

                            Lead Product(s) : Milademetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Guggenheim Securities

                            Deal Size : $50.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Rain Oncology

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Rain Oncology

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Milademetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rain Therapeutics Announces a Poster Presentation at the 34th EORTC/AACR/NCI Symposium

                            Details : Rain-32 (Milademetan), an oral small molecule, inhibitor of mouse double minute 2 is being developed in patients with wildtype tumor protein 53 (p53) cancers that are also exhibiting MDM2 dependence.

                            Brand Name : Rain-32

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 26, 2022

                            Lead Product(s) : Milademetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Rain Oncology

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Rain Oncology

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Milademetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma

                            Details : Milademetan (also known as RAIN-32) is an oral small molecule, inhibitor of the MDM2-p53 complex that reactivates p53. Milademetan has already demonstrated antitumor activity in an MDM2-amplified subtype of LPS and other solid tumors.

                            Brand Name : RAIN-32

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 04, 2022

                            Lead Product(s) : Milademetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth